Financial Analysis: Dyne Therapeutics (NASDAQ:DYN) vs. Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS:OSIR – Get Free Report) and Dyne Therapeutics (NASDAQ:DYN – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

0.3% of Osiris Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 43.4% of Osiris Therapeutics shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Osiris Therapeutics and Dyne Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Osiris Therapeutics and Dyne Therapeutics, as provided by MarketBeat.

Dyne Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 33.62%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Osiris Therapeutics.

Profitability

This table compares Osiris Therapeutics and Dyne Therapeutics’ net margins, return on equity and return on assets.

Summary

Dyne Therapeutics beats Osiris Therapeutics on 5 of the 8 factors compared between the two stocks.

About Osiris Therapeutics

(Get Free Report)

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.